Close
Enter your
text here
Monthly Archives :

September 2026

Supporting Brain Development While the Lungs Heal
 Supporting Brain Development While the Lungs Heal 1024 683 Pam Georgiana
By: Pam Georgiana
Baby with tracheostomy tube happily engaging with medical team who are holding a toy and wearing masks and gowns.

A new review presents a practical framework for incorporating neurodevelopmental care into the management of infants with severe bronchopulmonary dysplasia. For infants with severe bronchopulmonary dysplasia (BPD), months in the Newborn Intensive Care Unit (NICU) can coincide with a critical period of brain development. Although treating severe lung disease is essential, clinicians at Nationwide Children’s…

Mutation-Specific Therapy Brings New Hope for Patient With Duchenne Muscular Dystrophy
 Mutation-Specific Therapy Brings New Hope for Patient With Duchenne Muscular Dystrophy 1024 484 Abbie Miller
By: Abbie Miller
A man with Duchenne muscular dystrophy sits in a wheelchair between two family members

Justin Nicholoff is the first patient at Nationwide Children’s to receive del-zota through a managed access program. Since research into exon skipping therapies for Duchenne muscular dystrophy (DMD) took off about 15 years ago, Justin Nicholoff has waited for a therapy designed for his specific genetic mutation. In June, his wait ended as he became…

Brain Imaging Study Reveals Unexpected Glymphatic Pattern in Adolescent Psychosis
 Brain Imaging Study Reveals Unexpected Glymphatic Pattern in Adolescent Psychosis 1024 683 Katie Brind'Amour, PhD, MS, CHES
By: Katie Brind'Amour, PhD, MS, CHES
MRI or magnetic resonance image of head and brain scan. Close up view, toned image

Higher glymphatic imaging markers in adolescents contrast with patterns reported in adult studies, highlighting the importance of developmental stage for biomarker interpretation. A new neuroimaging study from investigators at Nationwide Children’s Hospital suggests that adolescents with first-episode of psychosis (FEP) may have increased activity in the brain’s glymphatic (waste clearance) system as measured by an…

Insurance-Driven Switches to Adalimumab Biosimilars Maintain Disease Control in Pediatric Inflammatory Bowel Disease
 Insurance-Driven Switches to Adalimumab Biosimilars Maintain Disease Control in Pediatric Inflammatory Bowel Disease 1024 683 Pam Georgiana
By: Pam Georgiana
Woman in scrubs with a stethoscope talking with teen.

New pediatric data may help clinicians reassure patients and families about nonmedical treatment switches Since biosimilar versions of adalimumab became available in the United States in 2023, more insurers have required patients receiving the originator medication to switch to a biosimilar. Researchers have deemed biosimilars safe and effective alternatives in adults. However, there is limited…